Workshop on Technology TransferWHO HQ
Geneva, November 30th – December 1st, 2010.
ARVAC project: the “Enabling Platform” model
Jean-Marie Préaud
2
PATH’s vaccine development projects• Pneumococcal
disease
• Diarrheal disease
• Rotavirus
• Enterotoxigenic E. coli and Shigella
• Influenza
• Malaria
• Meningococcal disease
• JapaneseEncephalitis
Ph
oto
: PA
TH
3
History - Strategy
• 2006: Grant from BMGF to develop Rotavirus Vaccines
• 2006: « Advancing Rotavirus VACcines » (ARVAC) project islaunched:
• 2007: Bill Wainright (Scientific Advisor) proposed the innovative concept of « Enabling Platform »:
• This toolbox of technologies, training, methodologies, and material is designed to meet common needs among emerging vaccine manufacturers and maximize global availability of rotavirus vaccines.
4
Organizational model: the « Enabling Platform »
• The “Enabling Platform” is a pool of (1) organizations, (2) consultants and (3) PATH experts with specific expertise to assist the four BRV manufacturers:
• Butantan,
• Shantha,
• Serum Institute of India and
• Wuhan Institute of Biological Products.
5
Organizations
Assays used in ClinicCMC
Process DevelopmentIDT
FormulationARIDIS + PATH Technology Solutions
Reagents for characterizationMCRI
QC testing on Vero Cells Banks and Virus
Seeds
CRL + Texcell
Qualified Vero CellsATCC
Assays; sCMV
Sequencing, detection of PCV
NIH (Dr Kapikian)
NIH (Dr Patton)
ContributionsOrganizations
6
Consultants
ExpertiseConsultants
Statistics, clinical design R. Kohberger
Clinical assaysR. Ward, M. McNeal
Regulatory, DCGI and WHO PQG. Spizzamiglio
Clinical developmentD. West
Validation of QC assays
GMP, QMS
A. Goldenthal, N. Harjee
Pre-clinical, tox studiesE. Rommel
Process, manufacture and QCW. Wainright
7
PATH experts
Project ManagementG. Thiry, M. Socquet (Ferney)
PackagingOptimize (Ferney). M. Zaffran, S.
Zipursky
FormulationD. Chen, M. Lal (Technical Solutions-
Seattle)
Process and ManufacturingJM Preaud (Ferney)
Clinical, immunology, vaccine
development
J. Boslego, D. Steele, J. Flores, K.
Lewis (DC –Seattle)
G. Thiry (Director ARVAC)
ExpertisePATH experts
8
Rotavirus partnerships
9
On going activities (1) : Process development at IDT
• IDT Biologika, Dessau, Germany
• Objective: IDT-Biologika is developing a process for production in Vero fixed on micro-carriers, in bioreactor, and compares this technology with flasks.
• The goal of this work is to optimize and to compare the mostefficient upstream technologies in terms of virus replication
capacity, costs, aseptic procedures and scalability.
• Manufacturers received the reports
10
On going activities (2) : QC testing at CRL and TEXCELL
• Charles River Laboratories (USA) and Texcell (France)
• Objective: CRL provided QC testing and characterization of
material on Vero cell banks, seeds and lots.
11
On going activities (3): Production of reagents atMCRI
• Murdoch Children Research Institute
• Production of a series of reagents for the testing of BRV Rota vaccines:
• 1. Monoclonal antibodies (directed to genotype G1, G2, G3, G4 and G9)
• 2. Reference standards (Bovine reassortant viruses)
• 3. Polyclonal antisera
• 4. Wildtype virus stocks – parental strains
• Achievements: material produced and sent to manufacturers
• Standardization of Immuno Fluorescence Assay test
12
On going activities (4): Formulation
• ARIDIS and PATH Technology Solutions
• Objective: development of full liquid all-in-one formulation
• Achievements: Aridis developed liquid formulations with the antacid buffer mixed with the rotavirus.
• Formulations were presented to manufacturers at the Annual BRV Meeting (Bangkok, June 09).
• Technology Solutions Lab ( TS, PATH Seattle) further developed these formulations and blending procedure. TS met with manufacturers for technical assistance in the preparation of the liquid formulation .
13
On going activities (5): Clinical assays
• CMC Vellore
• Objective: Production of reagents for clinical assays, training, QC
• Achievements: Production of reagents completed, Training on going.
14
Support by PATH
• Product Development
• Design of new GMP pilot facilities for cell cultivation area and viral area for Rota vaccine development
• Training and implementation of Quality Management Systems, Good Manufacturing Practices, EnvironmentalMonitoring Program
• Qualification of facilities and equipment
• Technical support for process development
• Technical support for formulation of full liquid vaccine
• Technical support for packaging and delivery systems
15
Support by PATH
• Pre-clinic, Clinical and Regulatory Development
• Support in preparation of Clinical Development Plan
• Design of pre-clinical package
• Preparation of tox studies
• Follow up of tox studies
• Review of protocols including statistics
• Validation of clinical assays
• Design of Phase 3 and operations
• Support in preparation of files for Phase 1
16
How to transfer know-how
• 4 manufacturers are active in the development of BRV vaccines: Butantan, Serum Institute of India, Shantha, Wuhan Institute of Biological Product and all have specific needs in terms of vaccine development
• PATH provides know-how through : Annual BRV ReviewMeetings, periodic visits to Manufacturers, ad hoc support according to specific needs
• PATH provides general documentation and assistance in termsof vaccine development, testing, formulation, packaging, clinicaldevelopment, regulatory
• For the benefit of all manufacturers in terms of time saving and coherence of BRV network
17
Conclusions
• PATH ARVAC has a large experience in the development of Rotavirus vaccines and provides technical support and monitoring through internally expertise, through a network of consultants and through a network of sub contractors.
18
Annual BRV Meeting – Kuala Lumpur, June 2010
Thank you !
Jean-Marie PréaudSenior Technical Officer [email protected]
0033 450 280 8350033 673 790 437
www.path.org